|
Gene: ZNF530 |
Gene summary for ZNF530 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ZNF530 | Gene ID | 348327 |
Gene name | zinc finger protein 530 | |
Gene Alias | ZNF530 | |
Cytomap | 19q13.43 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q6P9A1 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
348327 | ZNF530 | HCC1 | Human | Liver | HCC | 9.63e-03 | 2.31e+00 | 0.5336 |
348327 | ZNF530 | HCC2 | Human | Liver | HCC | 2.47e-19 | 1.52e+00 | 0.5341 |
348327 | ZNF530 | HCC5 | Human | Liver | HCC | 2.05e-12 | 8.21e-01 | 0.4932 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZNF530 | SNV | Missense_Mutation | novel | c.428N>G | p.Glu143Gly | p.E143G | Q6P9A1 | protein_coding | tolerated(0.07) | benign(0.111) | TCGA-NK-A5CR-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ZNF530 | SNV | Missense_Mutation | novel | c.182N>G | p.Asp61Gly | p.D61G | Q6P9A1 | protein_coding | tolerated(0.06) | benign(0.05) | TCGA-CR-6491-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | carboplatin | PD |
ZNF530 | SNV | Missense_Mutation | c.1439N>C | p.Arg480Pro | p.R480P | Q6P9A1 | protein_coding | tolerated(0.16) | possibly_damaging(0.831) | TCGA-CV-7245-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
ZNF530 | SNV | Missense_Mutation | novel | c.418N>A | p.Asp140Asn | p.D140N | Q6P9A1 | protein_coding | tolerated(0.16) | benign(0) | TCGA-D6-6516-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ZNF530 | SNV | Missense_Mutation | novel | c.449G>T | p.Gly150Val | p.G150V | Q6P9A1 | protein_coding | tolerated(0.66) | benign(0) | TCGA-F7-7848-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ZNF530 | insertion | Frame_Shift_Ins | novel | c.1304_1305insCTCCAGTGTGAAC | p.Glu436SerfsTer5 | p.E436Sfs*5 | Q6P9A1 | protein_coding | TCGA-CN-A497-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | ||
ZNF530 | SNV | Missense_Mutation | c.824N>T | p.Ser275Leu | p.S275L | Q6P9A1 | protein_coding | tolerated(0.14) | benign(0.326) | TCGA-KK-A59V-01 | Prostate | prostate adenocarcinoma | Male | <65 | 9 | Unknown | Unknown | SD | |
ZNF530 | SNV | Missense_Mutation | novel | c.449G>A | p.Gly150Glu | p.G150E | Q6P9A1 | protein_coding | tolerated(1) | benign(0.001) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
ZNF530 | SNV | Missense_Mutation | c.319N>C | p.Ile107Leu | p.I107L | Q6P9A1 | protein_coding | tolerated(0.09) | benign(0.005) | TCGA-BR-8286-01 | Stomach | stomach adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
ZNF530 | SNV | Missense_Mutation | c.751N>G | p.Ser251Gly | p.S251G | Q6P9A1 | protein_coding | tolerated(0.3) | benign(0.041) | TCGA-BR-8589-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |